SCHEMBL6204873

SCHEMBL6204873

O=C1c2ccc(Cl)cc2CC1(F)F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METAP1 P53582 2/20 0.43
PPOX P50336 1/20 0.41
S100A4 P26447 2/20 0.41
SRD5A1 P18405 3/20 0.41
AHR P35869 2/20 0.41
DRD2 P14416 3/20 0.39
HTR2A P28223 3/20 0.39
HTR2C P28335 3/20 0.39
HTR2B P41595 1/20 0.39
SIGMAR1 Q99720 1/20 0.39
CES1 P23141 1/20 0.38
SRD5A2 P31213 2/20 0.38
CMA1 P23946 1/20 0.37
HTT P42858 1/20 0.36
TDP2 O95551 1/20 0.36
HTR1A P08908 2/20 0.36
DRD4 P21917 2/20 0.36
HTR7 P34969 2/20 0.36
MAPT P10636 1/20 0.36
F7 P08709 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29237788 0.82 METAP1 (0.41) METAP1PPOXS100A4SRD5A1AHR
SCHEMBL6205926 0.82 METAP1 (0.41) METAP1PPOXS100A4SRD5A1AHR
SCHEMBL29237727 0.78 METAP1 (0.38) METAP1PPOXS100A4SRD5A1AHR
SCHEMBL31030947 0.78 METAP1 (0.38) METAP1PPOXS100A4SRD5A1AHR
SCHEMBL29237729 0.78 METAP1 (0.38) METAP1PPOXS100A4SRD5A1AHR
SCHEMBL29448019 0.78 METAP1 (0.43) METAP1PPOXS100A4SRD5A1AHR
SCHEMBL20951531 0.78 CASP1 (0.47) S100A4HTTTDP2MAPTPARP1
SCHEMBL20951823 0.78 TDP2 (0.46) METAP1S100A4SRD5A1AHRCES1
SCHEMBL14430319 0.78 METAP1 (0.43) METAP1PPOXS100A4SRD5A1AHR
SCHEMBL25309133 0.77 PPOX (0.42) METAP1PPOXS100A4SRD5A1AHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1157014-B1 POLYCYCLIC 2-AMINO-DIHYDROTHIAZOLE SYSTEMS, METHOD FOR THE PRODUCTION THEREOF AND THEIR UTILIZATION AS MEDICAMENT AVENTIS PHARMA GMBH (DE) 2005-08-24 EP disclosed
EP-1098891-B1 POLYCYCLIC THIAZOLIDIN-2-YLIDENE AMINES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS AVENTIS PHARMA GMBH (DE) 2005-08-10 EP disclosed
EP-1157014-A1 POLYCYCLIC 2-AMINO-DIHYDROTHIAZOLE SYSTEMS, METHOD FOR THE PRODUCTION THEREOF AND THEIR UTILIZATION AS MEDICAMENT Aventis Pharma Deutschland GmbH (DE) 2001-11-28 EP disclosed
US-6235763-B1 THERAPY FOR EATING DISORDERS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2001-05-22 US disclosed
EP-1098891-A1 POLYCYCLIC THIAZOLIDIN-2-YLIDENE AMINES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS Aventis Pharma Deutschland GmbH (DE) 2001-05-16 EP disclosed
US-6159996-A Polycyclic thiazolidin-2-ylidene amines, process for their preparation, and their use as pharmaceuticals AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2000-12-12 US disclosed
WO-2000051994-A1 POLYCYCLIC 2-AMINO-DIHYDROTHIAZOLE SYSTEMS, METHOD FOR THE PRODUCTION THEREOF AND THEIR UTILIZATION AS MEDICAMENT AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2000-09-08 WO disclosed
WO-2000004006-A1 POLYCYCLIC THIAZOLIDIN-2-YLIDENE AMINES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2000-01-27 WO disclosed